Core Viewpoint - The stock of Chengdu Olin Biological Technology Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days from August 18 to August 20, 2025, prompting the company to conduct a self-examination and confirm the normality of its business operations [1][3][4]. Group 1: Business Operations - The company confirmed that its daily operations are normal, with no significant changes or fluctuations in production costs and sales [1][2][3]. - The company is actively progressing in product research, production, and sales, with no major adjustments in the market environment or industry policies [1][2]. Group 2: Major Events - As of the announcement date, the company reported no undisclosed significant information or ongoing major asset restructuring, share issuance, or other substantial events [2][3]. - The company has not identified any media reports or market rumors that could significantly impact its stock price [2][3]. Group 3: Stock Performance - The closing price of the company's stock on August 20, 2025, was 33.11 yuan per share, with a significant price increase compared to most peers in the industry and the Shanghai Composite Index [3][5]. - The company's rolling price-to-earnings (P/E) ratio is 338.72, which is significantly higher than the industry average P/E ratio of 32.11, indicating a potential short-term market overheating risk [3][5].

New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (600399) has a tender offer period from August 12, 2025, to September 10, 2025[1] - Changcheng Military Industry (601606) announced a significant event on August 14, 2025[1] Market Alerts - Dongxin Co., Ltd. (688110) reported severe abnormal fluctuations on August 16, 2025[1] - ST Suwu (600200) has an announcement dated August 21, 2025, regarding market conditions[1] - Yunnan Zhiye (002428) and other companies have recent announcements on August 21, 2025, indicating market activity[1] Financial Performance - ST Jiangsu (600021) reported significant fluctuations on August 20, 2025, with a notable announcement[1] - ST Huanrong (600421) has an announcement dated August 20, 2025, reflecting market conditions[1] - ST Jinhong (000669) reported on August 20, 2025, indicating financial performance concerns[1]

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days from August 18 to August 20, 2025, indicating abnormal trading activity [2][3]. Group 1: Stock Trading Abnormalities - The company's stock price closed at 33.11 yuan per share as of August 20, 2025, with a recent cumulative increase that surpasses most peers in the industry and the Shanghai Composite Index [2][9]. - The rolling price-to-earnings (P/E) ratio for the company is reported at 338.72, significantly deviating from the industry average P/E ratio of 32.11 for the pharmaceutical manufacturing sector [2][9]. Group 2: Company Operations and Confirmations - The company conducted a self-examination and confirmed that its daily operations remain normal, with no significant changes or major events affecting its business [4][5]. - There are no undisclosed significant matters or ongoing major asset restructuring, share issuance, or other substantial corporate actions as of the announcement date [5][8]. Group 3: Market and Media Influence - The company has not identified any media reports or market rumors that could have significantly impacted its stock price, nor any leaks of undisclosed major information by company personnel [6][7].

（编辑 姚尧） 证券日报网讯 8月20日晚间，欧林生物发布公告称，公司股票于2025年8月18日、2025年8月19日、2025 年8月20日连续三个交易日收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动。经公司自查， 公司目前日常经营情况正常，未发生重大变化。经公司向控股股东、实际控制人书面询证，截至本公告 披露日，公司不存在应披露而未披露的重大信息。 ...

Core Viewpoint - Oulin Bio (688319) experienced a significant stock price increase, with a cumulative rise of over 30% in three consecutive trading days, leading to a classification of abnormal trading activity [1] Company Summary - Oulin Bio confirmed that its daily operations are normal and there have been no significant changes in its business [1] - The company conducted inquiries with its controlling shareholder and actual controller, confirming that there are no undisclosed major information as of the announcement date [1] - The recent stock price increase of Oulin Bio has outpaced most of its industry peers and the Shanghai Composite Index, indicating a potential short-term market overheating risk [1]

证券代码：688319 证券简称：欧林生物 公告编号：2025-039 成都欧林生物科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 一、股票交易异常波动的具体情况 公司股票于 2025 年 8 月 18 日、2025 年 8 月 19 日、2025 年 8 月 20 日连续三 个交易日收盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》 《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交 易异常波动的情形。 成都欧林生物科技股份有限公司股票于 2025 年 8 月 18 日、2025 年 8 月 19 日、2025 年 8 月 20 日连续三个交易日收盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异 常交易实时监控细则》的有关规定，属于股票交易异常波动的情形。 经公司自查，公司目前日常经营情况正常，未发生重大变化。经公司向 控股股东、实际控制人书面询证，截至本公告披露日，公司不存在应披 露而 ...

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. is adjusting its fundraising plan to raise a total of 125.29 million yuan for a vaccine research and production base technology transformation project, down from 175.29 million yuan [1][2][4] Group 1: Trading Information - On August 19, 2025, Olin Biological's stock closed at 31.21 yuan, up 12.71%, with a turnover rate of 6.8% and a trading volume of 275,600 shares, amounting to a total transaction value of 831 million yuan [1] - The fund flow on August 19 showed a net outflow of 5.9961 million yuan from main funds, a net inflow of 24.9017 million yuan from speculative funds, and a net outflow of 18.9056 million yuan from retail investors [1][3] Group 2: Fundraising Plan - The company plans to issue A-shares through a simplified procedure, with the total investment for the vaccine research and production base technology transformation project set at 290 million yuan, of which 125.29 million yuan will be raised through this issuance [3][4] - The number of shares to be issued has been adjusted from 12,785,769 shares to 9,138,795 shares, with the issue price set at 13.71 yuan per share [2][5] Group 3: Project Impact - The project aims to enhance the automation level and production efficiency of the production line, ensuring product quality and safety, and meeting market demand to strengthen the company's competitive advantage [3][4] - The company has committed to measures to mitigate the dilution of immediate returns from this issuance, including increasing R&D investment and accelerating the construction of the funded projects [5]

欧林生物8月19日大宗交易平台共发生2笔成交，合计成交量47.79万股，成交金额1059.03万元。成交价 格均为22.16元，相对今日收盘价折价29.00%。 证券时报·数据宝统计显示，欧林生物今日收盘价为31.21元，上涨12.71%，日换手率为6.80%，成交额 为8.31亿元，全天主力资金净流出682.48万元，近5日该股累计上涨52.24%，近5日资金合计净流入 9091.51万元。 两融数据显示，该股最新融资余额为2.59亿元，近5日增加4039.54万元，增幅为18.47%。（数据宝） 8月19日欧林生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 33.60 | 744.58 | 22.16 | -29.00 | 华泰证券股份有限公司成 | 华泰证券股份有限公司成 | | | | | | 都人民南路证券营业部 | 都人民南路证券营业部 | | 14.19 ...

8月19日，欧林生物大宗交易成交47.79万股，成交额1059.03万元，占当日总成交额的1.26%，成交价22.16元，较市场收盘价31.21元折价29%。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) | 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-19 | 欧林生物 | 688319 | 22.16 | 744.58 | 33.6 | 华泰证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司成都人民南路 | 公司成都人民南路 | | | | | | | | 证券营业部 | 证券营业部 | | 2025-08-19 | 欧林生物 | 688319 | 22.16 | 314.45 | 14.19 | 华泰证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司成都人民南路 | 公司成都人民南路 | | | | | | | | 证券营业部 | 证券营业部 | ...

Market Overview - The biopharmaceutical sector increased by 0.27% on August 19, with Olin Bio leading the gains [1] - The Shanghai Composite Index closed at 3727.29, down 0.02%, while the Shenzhen Component Index closed at 11821.63, down 0.12% [1] Top Performers - Olin Bio (688319) closed at 31.21, up 12.71% with a trading volume of 275,600 shares and a transaction value of 831 million [1] - Nossland (430047) closed at 28.44, up 11.53% with a trading volume of 211,700 shares and a transaction value of 622 million [1] - Ganli Pharmaceutical (603087) closed at 68.03, up 6.95% with a trading volume of 406,100 shares and a transaction value of 2.793 billion [1] Underperformers - Junshi Biosciences (688180) closed at 45.32, down 3.70% with a trading volume of 210,400 shares and a transaction value of 977 million [2] - ZhiXiangQuanTai (688443) closed at 33.05, down 3.42% with a trading volume of 77,200 shares and a transaction value of 260 million [2] - SanShengGuoJian (688336) closed at 54.10, down 2.50% with a trading volume of 85,900 shares and a transaction value of 477 million [2] Capital Flow - The biopharmaceutical sector saw a net inflow of 250 million from institutional investors, while retail investors experienced a net outflow of 379 million [2][3] - Major stocks like Shenzhou Cell (688520) had a net inflow of 1.39 billion from institutional investors, but a net outflow of 1.08 billion from retail investors [3]